These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16595824)

  • 21. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
    Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N
    Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular diagnostics of acute intermittent porphyria.
    Kauppinen R
    Expert Rev Mol Diagn; 2004 Mar; 4(2):243-9. PubMed ID: 14995910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry.
    Benton CM; Couchman L; Marsden JT; Rees DC; Moniz C; Lim CK
    Biomed Chromatogr; 2012 Aug; 26(8):1033-40. PubMed ID: 22740490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
    Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ
    JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of 5-aminolaevulinic acid dehydratase activity in erythrocytes and porphobilinogen in urine by micellar electrokinetic capillary chromatography.
    Luo JL; Deka J; Lim CK
    J Chromatogr A; 1996 Jan; 722(1-2):353-7. PubMed ID: 9019304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
    Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excretion of porphyrins and porphyrin precursors during neuromuscular paralysis produced by dithiobiuret.
    Atchison WD; Peterson RE
    Exp Neurol; 1984 Jul; 85(1):63-8. PubMed ID: 6428932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.
    San Juan I; Pereira-Ortuzar T; Cendoya X; Laín A; To-Figueras J; Mateos B; Planes FJ; Bernardo-Seisdedos G; Mato JM; Millet O
    Biochemistry; 2022 Nov; 61(21):2409-2416. PubMed ID: 36241173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute intermittent porphyria: psychosis as the only clinical manifestation.
    Ellencweig N; Schoenfeld N; Zemishlany Z
    Isr J Psychiatry Relat Sci; 2006; 43(1):52-6. PubMed ID: 16910386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haem precursor effects on [3H]-PK 11195 binding to platelets.
    Odber J; Cutler M; Dover S; Moore MR
    Neuroreport; 1994 May; 5(9):1093-6. PubMed ID: 8080964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: Results from a case-control study in northern Norway.
    Storjord E; Dahl JA; Landsem A; Ludviksen JK; Karlsen MB; Karlsen BO; Brekke OL
    Mol Genet Metab; 2019 Nov; 128(3):254-270. PubMed ID: 30583995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute intermittent porphyria: diagnosis per chance.
    Soundravally R; Goswami K; Nandeesha H; Koner BC; Sethuraman KR
    Indian J Pathol Microbiol; 2008; 51(4):551-2. PubMed ID: 19008594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria.
    Storjord E; Wahlin S; Karlsen BO; Hardersen RI; Dickey AK; Ludviksen JK; Brekke OL
    Life (Basel); 2023 Dec; 14(1):. PubMed ID: 38276268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. delta-Aminolevulinic acid effects on neuronal and glial tumor cell lines.
    Helson L; Braverman S; Mangiardi J
    Neurochem Res; 1993 Dec; 18(12):1255-8. PubMed ID: 8272191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anesthetic management of a patient with a history of acute intermittent porphyria and an elevation of urinary porphobilinogen].
    Hiraki T; Oishi K; Kano T
    Masui; 2001 Aug; 50(8):882-5. PubMed ID: 11554022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies in porphyria. V. Drug oxidation rates in hereditary hepatic porphyria.
    Anderson KE; Alvares AP; Sassa S; Kappas A
    Clin Pharmacol Ther; 1976 Jan; 19(1):47-54. PubMed ID: 1245093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurological complications of acute intermittent porphyria.
    Kuo HC; Huang CC; Chu CC; Lee MJ; Chuang WL; Wu CL; Wu T; Ning HC; Liu CY
    Eur Neurol; 2011; 66(5):247-52. PubMed ID: 21986212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circadian rhythms in acute intermittent porphyria--a pilot study.
    Larion S; Caballes FR; Hwang SI; Lee JG; Rossman WE; Parsons J; Steuerwald N; Li T; Maddukuri V; Groseclose G; Finkielstein CV; Bonkovsky HL
    Eur J Clin Invest; 2013 Jul; 43(7):727-39. PubMed ID: 23650938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.